Sifón M.D.R. · Marcolini N. · Barber M.J. ·
Mc Lean I. · Rizzo M. · Riveros S. · Costanzo M.V. · Nervo A. · Crimi G. · Perazzo F. · Levy E.M. ·
Mandó P.
Log in to MyKarger to check if you already have access to this content.
Buy
FullText & PDF
Unlimited re-access via MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *
Select
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Learn more
Rent/Cloud
Rent for 48h to view
Buy Cloud Access for unlimited viewing via different devices
Synchronizing in the ReadCube Cloud
Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Select
Subscribe
Access to all articles of the subscribed year(s) guaranteed for 5 years
Unlimited re-access via Subscriber Login or MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
Subcription rates
Select
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
Abstract
Background: Breast cancer is a highly heterogeneous disease, with large differences in the risk of recurrence. An elevated neutrophil-lymphocyte ratio (NLR) is correlated with a poor prognosis in a variety of tumors, and although it is still controversial in breast cancer, there are multiple studies, including meta-analysis, suggesting this. The purpose of this study is to analyze the prognostic value of preoperative NLR in an Argentine population of patients with non-metastatic breast cancer, not exposed to neoadjuvant treatment. Methods: Retrospective multicenter cohort study that includes patients over 18 years of age from three centers in the city and province of Buenos Aires who have had surgery for early breast cancer between 1/1/1999 and 12/31/2014. Based on the previous literature, a cut-off value of 2.0 was defined. Results: A total of 791 patients were eligible for analysis. Median age was 55 years old (IQR 45 - 65). Median NLR was 1.92 (IQR 1.50 – 2.56). The distribution of groups according to the 8th edition of the AJCC was 54.1% for stage I, 35.6% stage II and 10.4% stage III. Among the different tumor phenotypes, 79.0% were HR+/HER2-, 11.4% HR+or-/HER2+ and 9.2% HR-/HER2-. With a median follow up of 5.3 years, 112 patients (14.2%) had disease recurrence. Stage III patients had a higher NLR than stage I and II patients (p=0.002). The rest of the clinical and pathological characteristics did not show differences in the groups according to NLR. There were no differences in relapse-free survival according to NLR (p=0.37) and this did not change after adjusting for other prognostic variables. Conclusion: We consider it is important to determine the efficacy of prognostic markers that are easily accessible and of simple, systematic application. However, NLR does not appear to be an independent prognostic factor for recurrence in our population. In this sense, we consider it is important to publish negative results in order to avoid publication bias.
S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)